Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

MLA

David Raben, et al. “Position of a Panel of International Lung Cancer Experts on the Approval Decision for Use of Durvalumab in Stage III Non-Small-Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).” Annals of Oncology, vol. 30, no. 2, Feb. 2019, pp. 161–65. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....865e53fca13b5836883fb1f722438977&authtype=sso&custid=ns315887.

APA

David Raben, Luis Paz-Ares, Egbert F. Smit, Marina Chiara Garassino, S. Vallone, Albrecht Stenzinger, David Planchard, Matthias Guckenberger, Solange Peters, Enriqueta Felip, C. Le Pechoux, Dirk De Ruysscher, Nicolas Girard, J.B.A.G. Haanen, Rolf A. Stahel, Urania Dafni, Corinne Faivre-Finn, Mahmut Ozsahin, Michael Boyer, … Charles Swanton. (2019). Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). Annals of Oncology, 30(2), 161–165.

Chicago

David Raben, Luis Paz-Ares, Egbert F. Smit, Marina Chiara Garassino, S. Vallone, Albrecht Stenzinger, David Planchard, et al. 2019. “Position of a Panel of International Lung Cancer Experts on the Approval Decision for Use of Durvalumab in Stage III Non-Small-Cell Lung Cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).” Annals of Oncology 30 (2): 161–65. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....865e53fca13b5836883fb1f722438977&authtype=sso&custid=ns315887.